Targets › ALPL
1 program from 1 company in 3 trials: 3 Phase 3; Metabolic and endocrine; next expected readout Feb 2028.
Alkaline phosphatase that metabolizes various phosphate compounds and plays a key role in skeletal mineralization and adaptive thermogenesis. Has broad substrate specificity and can hydrolyze a considerable variety of compounds: however, only a few substrates, such as diphosphate (inorganic pyrophosphate; PPi), phosphocholine, phosphoethanolamine, pyridoxal 5'-phosphate (PLP) and N-phosphocreatine are natural…. (UniProt, P05186)
Open in Phaseline: the race on ALPL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | ALXN1850 Alkaline phosphatase enzyme replacement therapy | ALPL | Phase 3 | Hypophosphatasia | Feb 2028 |
Hypophosphatasia (3)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.